THC for Psychosis Risk

Palo Alto (17 mi)

Overseen byMohini Ranganathan, MD

Age: 18 - 65

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Yale University

No Placebo Group

Trial Summary

What is the purpose of this trial?The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.

Eligibility Criteria

This trial is for people who have tried cannabis at least once and are medically and mentally healthy. They must also have a relative with a confirmed psychotic disorder. It's not specified who can't join, but typically those with health issues that could interfere would be excluded.

Inclusion Criteria

I have a family member with a confirmed psychotic disorder.

Treatment Details

The study aims to see if having a family history of psychosis affects how the body responds to THC, an active component of cannabis. Participants will receive either very low dose THC, low dose THC, or a placebo without knowing which one they're getting.

2Treatment groups

Experimental Treatment

Group I: No Family History of Psychosis (FHN)Experimental Treatment3 Interventions

Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.

Group II: Family History of Psychosis (FHP)Experimental Treatment3 Interventions

Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.